tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR) and Cybin (CYBN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Citius Pharmaceuticals (CTXRResearch Report) and Cybin (CYBNResearch Report).

Citius Pharmaceuticals (CTXR)

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Pharmaceuticals yesterday and set a price target of $4.00. The company’s shares closed last Friday at $1.51, close to its 52-week low of $1.30.

According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of -18.4% and a 0.0% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, ATAI Life Sciences, and SeqLL.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target.

See today’s best-performing stocks on TipRanks >>

Cybin (CYBN)

Maxim Group analyst Jason McCarthy maintained a Hold rating on Cybin yesterday. The company’s shares closed last Friday at $1.06, close to its 52-week low of $0.82.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -25.7% and a 14.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Cybin is a Moderate Buy with an average price target of $8.24.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTXR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed